B+
Bull case
20%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
AUNA
AunaANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$5.80
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.20
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-21
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+75.3
Score
AI commentary
The post-earnings tone is mixed-to-negative: revenue and cash flow were strong, but the market focused on the EBITDA decline and margin compression. Secondary coverage reported a roughly 13%-14% premarket decline followed by substantial recovery; the $5.25 August 20 anchor remained below the prior session's close. Analyst revision evidence is unavailable, so the signal remains a low-coverage monitoring view rather than a confirmed rerating thesis.
RankAlpha Sentiment Codex - 2026-08-21
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-18eventMixed 2Q26 print reset the thesisMedium impact
Auna reported 2Q26 revenue of S/1,238 million, up 9% FX-neutral and 13% reported, while Adjusted EBITDA fell 9% FX-neutral to S/227 million and margin was 18.4%. Cash flow and leverage improved, but profitability pressure dominated the initial reaction. [#PR-2026-08-18]
2026-09-30eventCapacity and clinical-expansion milestonesHigh impact
Auna expects additional Montería capacity to be accretive through the remainder of 2026, a new linear accelerator in Monterrey to become operational in September, and the Versius robotic system to support high-complexity procedures in Peru. Execution and utilization are required before these investments support a rerating. [#PR-2026-08-18]
2026-12-31catalystH2 margin recovery and reaffirmed guidanceHigh impact
Management reaffirmed approximately 12% 2026 FX-neutral revenue growth and expects Adjusted EBITDA growth toward the low end of the 10%-14% range, excluding accepted Peru billing penalties. The key test is whether Mexico recovery, Colombia price adjustments and cost normalization convert volume growth into EBITDA. [#PR-2026-08-18]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-21 • Updated nightlySource: Internal modelMethodology